Eriochrome Black T inhibits endothelial cell growth through S-phase blockade

European Journal of Pharmacology

Volumn 399, Issue 2-3, 2000, Pages 85-90

  Langer, Ingrid ^a   Atassi, Ghanem ^a,b   Robberecht, Patrick ^a   Résibois, Anne ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Cell cycle; Cyclin; Endothelial cell; Eriochrome Black T; Suramin

Indexed keywords

CYCLIN D1; CYCLIN E; CYCLINE; ERIOCHROME BLACK T; SURAMIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; IN VITRO STUDY; PRIORITY JOURNAL; UMBILICAL VEIN;

AZO COMPOUNDS; CELL DIVISION; CELL LINE; CYCLIN D1; CYCLIN E; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOHISTOCHEMISTRY; PROLIFERATING CELL NUCLEAR ANTIGEN; S PHASE;

EID: 0034617399     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00370-8     Document Type: Article

References (23)

1. Baptist M., Dumont J.E., Roger P.P. Demonstration of cell cycle kinetics in thyroid primary culture by immunostaining of proliferating cell nuclear antigen: differences in cyclic AMP-dependent and -independent mitogenic stimulations. J. Cell Sci. 105:1993;69-80.
2. Beindl W., Mitterauer T., Hohenegger M., Ijzerman A.P., Nanoff C., Freissmuth M. Inhibition of receptor/G protein coupling by suramin analogues. Mol. Pharmacol. 50:1996;415-423.
3. Bojanowski K., Lelievre S., Markovits J., Couprie J., Jacquemin S.A., Larsen A.K. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc. Natl. Acad. Sci. U. S. A. 89:1992;3025-3029.
4. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 91:1994;4082-4085.
5. Danesi R., Del-Bianchi S., Soldani P., Campagni A., La-Rocca R.V., Myers C.E., Paparelli A., Del-Tacca M. Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br. J. Cancer. 68:1993;932-938.
6. Folkman J. Tumour angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1971;1182-1186.
7. Folkman J. What is the evidence that tumours are angiogenesis dependent? J. Natl. Cancer Inst. 82:1990;4-6.
8. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:1995;27-31.
9. Gagliardi A., Hadd H., Collins D.C. Inhibition of angiogenesis by suramin. Cancer Res. 52:1992;5073-5075.
10. Gastl G., Hermann T., Steurer M., Zmija J., Gunsilius E., Unger C., Kraft A. Angiogenesis as a target for tumour treatment. Oncology. 54:1997;177-184.
11. Hensey C.E., Boscoboinik D., Azzi A. Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett. 258:1989;156-158.
12. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 348:1990;555-557.
13. Jaffe E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52:1973;2745-2756.
14. Johnson D.G., Walker C.L. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 39:1999;295-312.
15. Kelman Z. PCNA: structure, functions and interactions. Oncogene. 14:1997;629-640.
16. La-Rocca R.V., Stein C.A., Myers C.E. Suramin: prototype of a new generation of antitumour compounds. Cancer Cells. 2:1990;106-115.
17. Morris A.D., Leonce S., Guilbaud N., Tucker G.C., Perez V., Jan M., Cordi A.A., Pierre A., Atassi G. Eriochrome Black T, structurally related to suramin, inhibits angiogenesis and tumour growth in vivo. Anticancer Drugs. 8:1997;746-755.
18. Nakajima M., DeChavigny A., Johnson C.E., Hamada J., Stein C.A., Nicolson G.L. Suramin. A potent inhibitor of melanoma heparanase and invasion. J. Biol. Chem. 266:1991;9661-9666.
19. Nelson N.J. Inhibitors of angiogenesis enter phase III testing. J. Natl. Cancer Inst. 90:1998;960-963.
20. Pluda J.M. Tumour-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin. Oncol. 24:1997;203-218.
21. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50:1998;413-492.
22. Voogd T.E., Vansterkenburg E.L., Wilting J., Janssen L.H. Recent research on the biological activity of suramin. Pharmacol. Rev. 45:1993;177-203.
23. Yang J., Kornbluth S. All aboard the cyclin train: subcellular trafficking of cyclins and their CDK partners. Trends Cell Biol. 9:1999;207-210.